1-3 of 3
Claudia Minotto, MD
Close
Sort by
Journal Articles

Similar Efficacy of Dasatinib and Nilotinib As Second-Line Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Failing Imatinib: A Retrospective, Real-Life Study

Mario Tiribelli, MD, Massimiliano Bonifacio, Gianni Binotto, MD, Alessandra Iurlo, MD, Francesca Cibien, MD, Elena Maino, MD, Anna Guella, MD, Gianluca Festini, MD, Claudia Minotto, MD, Ercole De Biasi, MD, Federico De Marchi, MD, Luigi Scaffidi, Luca Frison, MD, Cristina Bucelli, MD, Marta Medeot, MD, Elisabetta Calistri, MD, Mauro Krampera, Filippo Gherlinzoni, MD, Gianpietro Semenzato, Achille Ambrosetti, MD, Giovanni Pizzolo, Renato Fanin
Journal: Blood
Blood (2016) 128 (22): 5434.
https://doi.org/10.1182/blood.V128.22.5434.5434
Published: 2016
Journal Articles

Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: The Northern Italy Leukemia Group (NILG) Experience.

Irene M. Cavattoni, MD, Enrico Morello, MD, Michael Mian, MD, Elena Oldani, Biol.Sc., Tamara Intermesoli, MD, Erika Borlenghi, MD, Giuseppe Rossi, MD, Claudia Minotto, MD, Elisabetta Terruzzi, MD, Enrico Maria Pogliani, Ernesta Audisio, MD, Filippo Marmont, MD, Alessandro Rambaldi, MD, Renato Bassan, MD, Sergio Cortelazzo, MD
Journal: Blood
Blood (2006) 108 (11): 5380.
https://doi.org/10.1182/blood.V108.11.5380.5380
Published: 2006
Journal Articles

Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL).

Renato Bassan, MD, Orietta Spinelli, BSc, Elena Oldani, BSc, Tamara Intermesoli, MD, Manuela Tosi, BSc, Giuseppe Rossi, MD, Enrico M. Pogliani, MD, Emanuele Angelucci, MD, Pietro Fabris, MD, Giorgio Lambertenghi-Deliliers, MD, Paola Polistena, MD, Eros Di Bona, MD, Fabio Ciceri, MD, Franco Leoni, MD, Claudia Minotto, MD, Daniele Mattei, MD, Maurizio Musso, MD, Tiziano Barbui, MD, Alessandro Rambaldi, MD
Journal: Blood
Blood (2005) 106 (11): 1836.
https://doi.org/10.1182/blood.V106.11.1836.1836
Published: 2005